Christine Rothe
Chief Development Officer iOmx
Christine Rothe serves as Chief Development Officer at iOmx Therapeutics where she is responsible for research and development of targeted cancer immune-therapy programs. Christine has a long-standing track record in discovery and development of drug candidates. Before joining iOmx, Christine held positions of increasing responsibility in R&D and Alliance Management at Pieris Pharmaceuticals and MorphoSys AG, playing a major role in shaping drug discovery processes and bringing therapeutics from the start of a program into the clinic.
Seminars
Wednesday 9th December 2026
FasTarg Enables Rapid Discovery of Clean Surface-Accessible, Tumour- Selective TCE Targets
9:00 am
- FasTarg is an ML/AI-assisted bioinformatics approach to identify novel TCE targets for solid tumour indications
- iOmx’s integrated discovery and development platform enables the generation ofhighly potent TCE compounds
- Show-casing a TCE program with potent tumour cell killing activity and a favourable safety profile
